| Prevention of bleeding in patients with atrial fibrillation undergoing PCI CM Gibson, R Mehran, C Bode, J Halperin, FW Verheugt, P Wildgoose, ... New England Journal of Medicine 375 (25), 2423-2434, 2016 | 1642 | 2016 |
| Safety and tolerability of CSL112, a reconstituted, infusible, plasma-derived apolipoprotein AI, after acute myocardial infarction: the AEGIS-I trial (ApoA-I event reducing in … C Michael Gibson, S Korjian, P Tricoci, Y Daaboul, M Yee, P Jain, ... Circulation 134 (24), 1918-1930, 2016 | 186 | 2016 |
| EMBRACE STEMI study: a Phase 2a trial to evaluate the safety, tolerability, and efficacy of intravenous MTP-131 on reperfusion injury in patients undergoing primary … CM Gibson, RP Giugliano, RA Kloner, C Bode, M Tendera, A Jánosi, ... European heart journal 37 (16), 1296-1303, 2016 | 154 | 2016 |
| d-Dimer elevation and adverse outcomes R Halaby, CJ Popma, A Cohen, G Chi, MR Zacarkim, G Romero, ... Journal of thrombosis and thrombolysis 39, 55-59, 2015 | 147 | 2015 |
| The IMPROVEDD VTE risk score: incorporation of D-dimer into the IMPROVE score to improve venous thromboembolism risk stratification CM Gibson, AC Spyropoulos, AT Cohen, RD Hull, SZ Goldhaber, ... TH open 1 (01), e56-e65, 2017 | 130 | 2017 |
| Recurrent hospitalization among patients with atrial fibrillation undergoing intracoronary stenting treated with 2 treatment strategies of rivaroxaban or a dose-adjusted oral … CM Gibson, DS Pinto, G Chi, D Arbetter, M Yee, R Mehran, C Bode, ... Circulation 135 (4), 323-333, 2017 | 118 | 2017 |
| Extended-duration betrixaban reduces the risk of stroke versus standard-dose enoxaparin among hospitalized medically ill patients: an APEX trial substudy (acute medically ill … CM Gibson, G Chi, R Halaby, S Korjian, Y Daaboul, P Jain, D Arbetter, ... Circulation 135 (7), 648-655, 2017 | 70 | 2017 |
| Vitamin K2 supplementation and arterial stiffness among renal transplant recipients—a single-arm, single-center clinical trial AG Mansour, E Hariri, Y Daaboul, S Korjian, A El Alam, AD Protogerou, ... Journal of the American Society of Hypertension 11 (9), 589-597, 2017 | 69 | 2017 |
| The safety and efficacy of full-versus reduced-dose betrixaban in the Acute Medically Ill VTE (Venous Thromboembolism) Prevention With Extended-Duration Betrixaban (APEX) trial CM Gibson, R Halaby, S Korjian, Y Daaboul, DF Arbetter, MK Yee, ... American Heart Journal 185, 93-100, 2017 | 57 | 2017 |
| Asymptomatic deep vein thrombosis is associated with an increased risk of death: insights from the APEX trial A Kalayci, CM Gibson, G Chi, MK Yee, S Korjian, S Datta, T Nafee, ... Thrombosis and Haemostasis 118 (12), 2046-2052, 2018 | 52 | 2018 |
| Sickle cell nephropathy: an update on pathophysiology, diagnosis, and treatment E Hariri, A Mansour, A El Alam, Y Daaboul, S Korjian, S Aoun Bahous International Urology and Nephrology 50, 1075-1083, 2018 | 51 | 2018 |
| Comparison of fatal or irreversible events with extended‐duration betrixaban versus standard dose enoxaparin in acutely ill medical patients: an APEX trial substudy CM Gibson, S Korjian, G Chi, Y Daaboul, P Jain, D Arbetter, ... Journal of the American Heart Association 6 (7), e006015, 2017 | 49 | 2017 |
| The impact of the COVID-19 pandemic on cardiovascular fellows-in-training: a national survey P Rao, J Diamond, S Korjian, L Martin, M Varghese, JD Serfas, R Lee, ... Journal of the American College of Cardiology 76 (7), 871-875, 2020 | 43 | 2020 |
| The CSL112-2001 trial: safety and tolerability of multiple doses of CSL112 (apolipoprotein AI [human]), an intravenous formulation of plasma-derived apolipoprotein AI, among … CM Gibson, M Kerneis, MK Yee, Y Daaboul, S Korjian, AP Mehr, P Tricoci, ... American heart journal 208, 81-90, 2019 | 37 | 2019 |
| Safety and efficacy of double vs. triple antithrombotic therapy in patients with atrial fibrillation with or without acute coronary syndrome undergoing percutaneous coronary … G Gargiulo, CP Cannon, CM Gibson, A Goette, RD Lopes, J Oldgren, ... European Heart Journal-Cardiovascular Pharmacotherapy 7 (FI1), f50-f60, 2021 | 34 | 2021 |
| Haloperidol versus ondansetron for treatment of established nausea and vomiting following general anesthesia: a randomized clinical trial VG Yazbeck-Karam, SM Siddik-Sayyid, HB Barakat, S Korjian, MT Aouad Anesthesia & Analgesia 124 (2), 438-444, 2017 | 33 | 2017 |
| Medical education in a foreign language and history-taking in the native language in Lebanon–a nationwide survey V Abi Raad, K Raad, Y Daaboul, S Korjian, N Asmar, M Jammal, ... BMC medical education 16, 1-6, 2016 | 33 | 2016 |
| Cholesterol efflux capacity and its association with adverse cardiovascular events: a systematic review and meta-analysis JJ Lee, G Chi, C Fitzgerald, SHA Kazmi, A Kalayci, S Korjian, D Duffy, ... Frontiers in Cardiovascular Medicine 8, 774418, 2021 | 30 | 2021 |
| Rationale and design of Apo-I Event Reduction in Ischemic Syndromes I (AEGIS-I): a phase 2b, randomized, placebo-controlled, dose-ranging trial to investigate the safety and … CM Gibson, S Korjian, P Tricoci, Y Daaboul, JH Alexander, PG Steg, ... American Heart Journal 180, 22-28, 2016 | 29 | 2016 |
| Usefulness of rivaroxaban for secondary prevention of acute coronary syndrome in patients with history of congestive heart failure (from the ATLAS-ACS-2 TIMI-51 trial) S Korjian, E Braunwald, Y Daaboul, M Mi, DL Bhatt, FWA Verheugt, ... The American Journal of Cardiology 122 (11), 1896-1901, 2018 | 26 | 2018 |
